CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals

Agenus shared on LinkedIn:

“‘With this infusion of capital, we are poised to accelerate the development of our lead therapeutic combination regimen, botensilimab/balstilimab, which we expect to make a significant impact in the treatment of MSS colorectal cancer.

This initiative brings us closer to our goal of dramatically improving cancer treatment for patients who are often left with limited or no options.’

Chairman and CEO Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals.”

Additional information.
Source: Agenus/LinkedIn